We synthesized and evaluated a series of 2,4-disubstituted furo[3,2-b]indole derivatives for anticancer activity and established the structure-activity relationships (SARs) of these compounds. Among all tested compounds, we found (5-((2-(hydroxymethyl)-4H-furo[3,2-b]indol-4-yl)methyl)furan-2-yl)methanol (10a) to be the most promising agent. In screening against NCI-60 human tumor cell lines, 10a exhibited highly selective anticancer activity and significant inhibitory activity against A498 renal cancer cells. Our COMPARE analysis results suggest that the 10a fingerprint is similar to that of NSC-754549, which is an isostere of YC-1. We further confirmed the significant antitumor activity of compound 10a with tests in the A498 xenograft nude mice model. Therefore, compound 10a should be further developed as a new drug candidate for treating renal cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejmech.2013.06.012 | DOI Listing |
Chem Biodivers
January 2025
St Xavier's College, Kolkata, Department of Chemistry, 30, Mother teresa Sarani, Kol-16, 700016, Kolkata, INDIA.
Amino-quinolines are potential candidates that may provide some insight into the current chemotherapeutic research due to their demonstrated anti-cancer activity. This led us to synthesize and explore a new amino-azo-quinoline ligand H2L 1 and its square planar nickel(II) complexes [Ni(HL)(OAc)], 2 and [Ni(HL)Cl], 3 and the structures were determined by SCXRD. Theoretical investigation of redox orbitals of the complexes discloses that the reduction process is due to ligand reduction whereas both metal and ligand are contributing towards oxidation.
View Article and Find Full Text PDFMikrochim Acta
January 2025
Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, 215123, Jiangsu, China.
A new methodology is presented for the rapid, specific, and sensitive detection of irinotecan (CPT-11), a chemotherapeutic agent utilized in the treatment of cancer, along with its metabolically active derivative, SN-38, via laser desorption/ionization mass spectrometry (LDI MS). The method includes the detection of camptothecin (CPT), which can be utilized as an internal standard for the quantitative assessment of both CPT-11 and SN-38 in mouse serum. The approach utilizes a plasmonic two-dimensional (2D) black phosphorus nanosheet (BPN)-gold nanomatrix (BP@Au) in LDI MS.
View Article and Find Full Text PDFAppl Biochem Biotechnol
January 2025
Department of Chemistry, College of Sciences for Women, University of Baghdad, Baghdad, Iraq.
Azo dye was used to prepare a new series of complexes with chlorides of rhodium (Rh), ruthenium (Ru), and corona (Au). The prepared materials were subjected to infrared, ultraviolet-visible, and mass spectrometry, as well as thermogravimetric analysis, differential calorimetry, and elemental analysis. Conductivity, magnetic susceptibility, metal content, and chlorine content of the complexes were also measured.
View Article and Find Full Text PDFDiscov Oncol
January 2025
Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, No.1367 Wenyi West Road, Yuhang District, Hangzhou, 311100, People's Republic of China.
The work is aimed to investigate whether midazolam functions in thyroid cancer and reveal the potential mechanism of action. Cell viability was detected by CCK-8 method when treated by varying doses of midazolam to detect the cytotoxicity of midazolam on human thyroid follicular epithelial cell line and thyroid cancer cell lines. In thyroid cancer cells, EDU staining, wound healing and transwell assays were respectively used to detect cell proliferation, migration and invasion.
View Article and Find Full Text PDFChemMedChem
January 2025
UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers, groupe « Systèmes Moléculaires Programmés », Faculté des Sciences Fondamentales et Appliquées, 4 rue Michel Brunet, TSA 51106, 86073, Poitiers, FRANCE.
The development of novel therapeutic strategies enabling the selective destruction of tumors while sparing healthy tissues is of great interest to improve the efficacy of cancer chemotherapy. In this context, we designed a β-glucuronidase-responsive albumin-binding prodrug programmed to release a potent Isocombretastatin A-4 analog within the tumor microenvironment. When injected at a non-toxic dose in mice bearing orthotopic triple-negative mammary tumors, this prodrug produced a significant anticancer activity, therefore offering a valuable alternative to the systemic administration of the parent drug.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!